Q3 EPS Estimates for 10x Genomics Raised by Leerink Partnrs

10x Genomics (NASDAQ:TXG - Free Report) - Stock analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for shares of 10x Genomics in a research report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.28). The consensus estimate for 10x Genomics' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics' Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.98) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.51) EPS and FY2027 earnings at ($0.26) EPS.

Several other equities analysts also recently commented on TXG. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday, July 12th. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Wall Street Zen cut shares of 10x Genomics from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Stephens reiterated an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $14.13.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $12.15 on Monday. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -9.35 and a beta of 2.03. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $24.76. The stock has a 50-day simple moving average of $10.60 and a 200-day simple moving average of $10.96.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 25.14% and a negative return on equity of 23.22%. The company had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same quarter last year, the business posted ($0.50) EPS. The company's revenue for the quarter was down 2.3% on a year-over-year basis.

Insider Activity

In other news, CFO Adam Taich sold 4,044 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the sale, the chief financial officer directly owned 331,588 shares of the company's stock, valued at $2,752,180.40. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 7,485 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the sale, the insider directly owned 448,374 shares in the company, valued at $3,721,504.20. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,872 shares of company stock valued at $173,238 over the last three months. 10.03% of the stock is owned by insiders.

Hedge Funds Weigh In On 10x Genomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC boosted its position in shares of 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock worth $193,206,000 after purchasing an additional 86,455 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 7.5% during the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock worth $112,143,000 after purchasing an additional 901,656 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of 10x Genomics by 1.7% during the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock worth $97,061,000 after acquiring an additional 184,537 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after acquiring an additional 4,987,195 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after acquiring an additional 4,371,327 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.